Board of Directors

Freeline is working with World leaders in the gene therapy field and the Company’s Board of Directors has commercial and scientific experience across all phases of drug development, as well as start-up success, and is committed to finding a cure for devastating genetic diseases.

Dr Chris Hollowood - Chairman

Chris is the Chief Investment Officer and a Managing Partner of Syncona Investment Management Ltd. Previously, he was a partner of Apposite Capital LLP, a venture and growth capital company focused on the healthcare and life science sector.
During his time at Apposite, he was involved in a number of investments, which included Ambit Biosciences (acquired by Daiichi Sankyo), Convergence Pharmaceuticals (acquired by Biogen-Idec), Birdrock and the acquisition of a portfolio of nine US healthcare companies which included Zonare Medical Systems (acquired by Mindray) and Ulthera (acquired by Merz). Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and as a medicinal chemist in the pharmaceutical industry.
Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from Cambridge University

Professor Amit Nathwani - Chief Scientific Officer

Amit is the CSO of Freeline and also the Director of the Katharine Dormandy Haemophilia Centre at the Royal Free Hospital and a Senior NIHR Investigator. He is also Professor of Haematology at UCL. He graduated in Medicine from the University of Aberdeen in 1984.In 1997 he moved to St. Jude Children’s Research Hospital, Memphis, Tennessee, USA to work with Dr Arthur Nienhuis on adeno-associated virus mediated gene transfer, which is where he started his pioneering work on gene therapy for haemophilia B. In 2001 he returned to University College London as a Senior Lecturer in Haematology and a Consultant to the National Blood Services in the UK. He was the first to show successful correction of bleeding diathesis in patients with severe haemophilia B using a distinct gene transfer approach developed in collaboration with Drs Davidoff and Nienhuis at St Jude Children’s Research Hospital.

Dr Richard Fagan - Non-Executive Director

Rick is the Director of BioPharm at UCL Business PLC. He became Director in 2007 after joining as Assistant Director in 2006. Previously he worked in the Target Discovery Departments of AstraZeneca, Sanofi-Aventis and Impharmatica where he worked very closely with the business development team. Rick is a cell and molecular biologist by training, gaining his PhD at McGill University, Canada followed by a post doctorate at the Imperial Cancer Research Fund, London, and then the National Institute for Medical Research.

Freeline Platform

Our proprietary and highly optimised platform is aiming to maximise clinical benefit for patients

Learn More >

Gene Therapy for Haemophilia

Gene therapy has the potential to transform people's lives by safely and continuously delivering clotting proteins to the blood

Learn More >

Freeline careers

Find out more about life at Freeline and current vacancies in our careers section

Learn More >